Since coming to the public markets in early 2013, Stemline Therapeutics (NASDAQ:STML) shareholders have experienced one heck of a ride. 
Source: BigCharts.com
The share price reached $47 on positive news for its leading drug candidate SL-401, with Roth Capital setting a $50 price target, Jefferies a $60 price target, Aegis a whopping $70 price target. Reasons for enthusiasm included the accelerated development of its lead candidate in an orphan designation and an estimated $500 million peak market potential in lead indication for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) according to Jefferies. Aegis analyst Raj Selvaraju claimed $800 million to $3 billion when taking potential expansion into AML (acute myeloid leukemia) into account.
